Aldeyra Therapeutics Revenue, Profits - ALDX Annual Income Statement

Add to My Stocks
$8.5 $0.45 (5.59%) ALDX stock closing price Sep 20, 2018 (Closing)

Financial analysis of Aldeyra Therapeutics involves more than just checking the Aldeyra Therapeutics stock price, by looking at the financial statements of the company in detail. The income statement gives the investor an understanding of the topline or revenue and bottomline or profit numbers of the company and helps investors evaluate if a company has been growing or not. The income statement is always for an accounting period, typically for a year or quarter, and affects the stock. In this case, the ALDX stock is bound to reflect the impact of the YOY decline of 0. The Aldeyra Therapeutics profit and loss statement for 2017 shows a net profit of $-22.34M. Profits for last year was $-18.69M. Apart from this an investor should also check Aldeyra Therapeutics assets and Aldeyra Therapeutics free cash flow.

View revenue and profit details for latest and last 10 financial years.
show more
Fiscal year is Jan - Dec20172016201520142013
Aldeyra Therapeutics Revenues or Net Sales
-----
Cost Of Goods Sold (COGS)-----
Aldeyra Therapeutics Gross Profit
-----
Research & Development Expense16.3M13.17M7.57M3.7M1.54M
Selling General & Admin Expense6.18M5.52M4.41M3.56M2.13M
Income Before Depreciation Depletion Amortization-22.48M-18.69M-11.98M-7.27M-3.67M
Depreciation Depletion Amortization-----
Non Operating Income---2.32M16.89M
Interest Expense-----
Aldeyra Therapeutics Pretax Income
-22.34M-18.69M-12.09M-5.18M13.06M
Provision for Income Taxes-----
MinorityInterest-----
Investment Gains Losses-----
Other Income-----
Income Before Extraordinaries & Disc Operations-22.34M-18.69M-12.09M-5.18M13.06M
Extraordinary Items & Discontinued Operations-----
Aldeyra Therapeutics Profit/ Loss (Net Income)
-22.34M-18.69M-12.09M-5.18M13.06M
Average Shares used to compute Diluted EPS15.92M11.35M8.63M3.85M-
Average Shares used to compute Basic EPS15.92M11.35M8.63M3.82M-
Income Before Nonrecurring Items-22.34M-18.7M-12.09M-5.19M-
Income from Nonrecurring Items-----
Aldeyra Therapeutics Earnings Per Share Basic Net
-1.40-1.65-1.40-2.51-
Aldeyra Therapeutics Earnings Per Share Diluted Net
-1.40-1.65-1.40-3.09-
EPS Diluted Before Nonrecurring Items-1.40-1.65-1.40-3.09-
Preferred Dividends Acc Pd-----
Dividends Common-----
Dividend Per Share Common0.000.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.

It is very helpful to read a report on Aldeyra Therapeutics stock analysis. An investor must check the following items in an income statement:

  • Revenue: This is the inflow that is generated from the sale of goods or services and is $- for this year of 2017. Our Aldeyra Therapeutics revenue chart gives a clear visual representation of how the topline or sales growth has been. Investors often invest only in those companies where the revenue is growing at a steady rate.
  • Bottom line: The word bottom line comes because it is usually the last line of the income statement and refers to the actual profits after deducting all expenses from the revenues. ALDX stock had a poor bottom line growth.

The income statement is also called statement of revenue and expense. The ALDX financials along with Aldeyra Therapeutics historical stock prices provide a lot of details about the firm.

Aldeyra Therapeutics Income Statement - Key Financial Ratios